Corrigendum to “Expression of tumor-related Rac1b antagonizes B-Raf-induced senescence in colorectal cells” [Cancer Lett. 369 (2015) 368–375, (S0304383515005686), (10.1016/j.canlet.2015.08.027)];Expression of tumor-related Rac1b antagonizes B-Raf-induced senescence in colorectal cells

Cancer Letters

Volumn 369, Issue 2, 2015, Pages 368-375

  Henriques, Andreia F A ^a,b   Barros, Patrícia ^a,b   Moyer, Mary Pat ^c   Matos, Paulo ^a,b   Jordan, Peter ^a,b  

^a NATIONAL INSTITUTE OF HEALTH DR RICARDO JORGE   (Portugal)

^b UNIVERSITY OF LISBON   (Portugal)

^c INCELL Corporation ^*  (United States)

Author keywords

B Raf; Colorectal cancer; Oncogene induced senescence; Rac1b; Tumor progression

Indexed keywords

B RAF KINASE; BETA GALACTOSIDASE; GUANOSINE TRIPHOSPHATASE; KI 67 ANTIGEN; PROTEIN P14; PROTEIN P15; PROTEIN P21; RAC1 PROTEIN; RAC1B PROTEIN; REACTIVE OXYGEN METABOLITE; UNCLASSIFIED DRUG;

ARTICLE; B RAF GENE; CELL AGING, CELL DEGENERATION AND CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; HUMAN; HUMAN CELL; ONCOGENE INDUCED SENESCENCE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; CELL AGING; COLORECTAL TUMOR; DISEASE COURSE; GENETIC TRANSFECTION; GENETICS; METABOLISM; PATHOLOGY; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

CELL AGING; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DISEASE PROGRESSION; HUMANS; PROTO-ONCOGENE PROTEINS B-RAF; RAC1 GTP-BINDING PROTEIN; SIGNAL TRANSDUCTION; TRANSFECTION;

EID: 84945476885     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2022.215936     Document Type: Erratum

References (47)

1. Fodde R., Smits R., Clevers H. APC, signal transduction and genetic instability in colorectal cancer. Nat. Rev. Cancer 2001, 1:55-67. 10.1038/35094067.
2. Cunningham J.M., Christensen E.R., Tester D.J., Kim C.Y., Roche P.C., Burgart L.J., et al. Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res 1998, 58:3455-3460.
3. Veigl M.L., Kasturi L., Olechnowicz J., Ma A.H., Lutterbaugh J.D., Periyasamy S., et al. Biallelic inactivation of hMLH1 by epigenetic gene silencing, a novel mechanism causing human MSI cancers. Proc. Natl. Acad. Sci. U.S.A. 1998, 95:8698-8702.
4. Shen L., Toyota M., Kondo Y., Lin E., Zhang L., Guo Y., et al. Integrated genetic and epigenetic analysis identifies three different subclasses of colon cancer. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:18654-18659. 10.1073/pnas.0704652104.
5. Weisenberger D.J., Siegmund K.D., Campan M., Young J., Long T.I., Faasse M.A., et al. CpG island methylator phenotype underlies sporadic microsatellite instability and is tightly associated with BRAF mutation in colorectal cancer. Nat. Genet 2006, 38:787-793. 10.1038/ng1834.
6. Snover D.C., Jass J.R., Fenoglio-Preiser C., Batts K.P. Serrated polyps of the large intestine: a morphologic and molecular review of an evolving concept. Am. J. Clin. Pathol 2005, 124:380-391. 10.1309/V2EP-TPLJ-RB3F-GHJL.
7. Kambara T. BRAF mutation is associated with DNA methylation in serrated polyps and cancers of the colorectum. Gut 2004, 53:1137-1144. 10.1136/gut.2003.037671.
8. Velho S., Moutinho C., Cirnes L., Albuquerque C., Hamelin R., Schmitt F., et al. BRAF, KRAS and PIK3CA mutations in colorectal serrated polyps and cancer: primary or secondary genetic events in colorectal carcinogenesis?. BMC Cancer 2008, 8:255. 10.1186/1471-2407-8-255.
9. Carr N.J., Mahajan H., Tan K.L., Hawkins N.J., Ward R.L. Serrated and non-serrated polyps of the colorectum: their prevalence in an unselected case series and correlation of BRAF mutation analysis with the diagnosis of sessile serrated adenoma. J. Clin. Pathol 2009, 62:516-518. 10.1136/jcp.2008.061960.
10. Kim K.-M., Lee E.J., Ha S., Kang S.Y., Jang K.-T., Park C.K., et al. Molecular features of colorectal hyperplastic polyps and sessile serrated adenoma/polyps from Korea. Am. J. Surg. Pathol 2011, 35:1274-1286. 10.1097/PAS.0b013e318224cd2e.
11. Boparai K.S., Dekker E., Polak M.M., Musler A.R., van Eeden S., van Noesel C.J.M. A serrated colorectal cancer pathway predominates over the classic WNT pathway in patients with hyperplastic polyposis syndrome. Am. J. Pathol 2011, 178:2700-2707. 10.1016/j.ajpath.2011.02.023.
12. Garnett M.J., Marais R. Guilty as charged: B-RAF is a human oncogene. Cancer Cell 2004, 6:313-319. 10.1016/j.ccr.2004.09.022.
13. Davies H., Bignell G.R., Cox C., Stephens P., Edkins S., Clegg S., et al. Mutations of the BRAF gene in human cancer. Nature 2002, 417:949-954. 10.1038/nature00766.
14. Wan P.T.C., Garnett M.J., Roe S.M., Lee S., Niculescu-Duvaz D., Good V.M., et al. Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF. Cell 2004, 116:855-867.
15. Pritchard C., Carragher L., Aldridge V., Giblett S., Jin H., Foster C., et al. Mouse models for BRAF-induced cancers. Biochem. Soc. Trans 2007, 35:1329-1333. 10.1042/BST0351329.
16. Dankort D., Filenova E., Collado M., Serrano M., Jones K., McMahon M. A new mouse model to explore the initiation, progression, and therapy of BRAFV600E-induced lung tumors. Genes Dev 2007, 21:379-384. 10.1101/gad.1516407.
17. Carragher L.A.S., Snell K.R., Giblett S.M., Aldridge V.S.S., Patel B., Cook S.J., et al. V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol. Med 2010, 2:458-471. 10.1002/emmm.201000099.
18. Rad R., Cadiñanos J., Rad L., Varela I., Strong A., Kriegl L., et al. A genetic progression model of Braf(V600E)-induced intestinal tumorigenesis reveals targets for therapeutic intervention. Cancer Cell 2013, 24:15-29. 10.1016/j.ccr.2013.05.014.
19. Collado M., Serrano M. The power and the promise of oncogene-induced senescence markers. Nat. Rev. Cancer 2006, 6:472-476. 10.1038/nrc1884.
20. Michaloglou C., Vredeveld L.C.W., Soengas M.S., Denoyelle C., Kuilman T., van der Horst C.M.A.M., et al. BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 2005, 436:720-724. 10.1038/nature03890.
21. Collado M., Gil J., Efeyan A., Guerra C., Schuhmacher A.J., Barradas M., et al. Tumour biology: senescence in premalignant tumours. Nature 2005, 436:642. 10.1038/436642a.
22. Kriegl L., Neumann J., Vieth M., Greten F.R., Reu S., Jung A., et al. Up and downregulation of p16(Ink4a) expression in BRAF-mutated polyps/adenomas indicates a senescence barrier in the serrated route to colon cancer. Mod. Pathol 2011, 24:1015-1022. 10.1038/modpathol.2011.43.
23. Gil J., Peters G. Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat. Rev. Mol. Cell Biol 2006, 7:667-677. 10.1038/nrm1987.
24. Jung Y.-S., Qian Y., Chen X. Examination of the expanding pathways for the regulation of p21 expression and activity. Cell. Signal 2010, 22:1003-1012. 10.1016/j.cellsig.2010.01.013.
25. Jordan P., Brazåo R., Boavida M.G., Gespach C., Chastre E. Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors. Oncogene 1999, 18:6835-6839. 10.1038/sj.onc.1203233.
26. Matos P., Oliveira C., Velho S., Gonçalves V., da Costa L.T., Moyer M.P., et al. B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival. Gastroenterology 2008, 135:899-906. 10.1053/j.gastro.2008.05.052.
27. Matos P., Collard J.G., Jordan P. Tumor-related alternatively spliced Rac1b is not regulated by Rho-GDP dissociation inhibitors and exhibits selective downstream signaling. J. Biol. Chem 2003, 278:50442-50448. 10.1074/jbc.M308215200.
28. Fiegen D., Haeusler L.-C., Blumenstein L., Herbrand U., Dvorsky R., Vetter I.R., et al. Alternative splicing of Rac1 generates Rac1b, a self-activating GTPase. J. Biol. Chem 2004, 279:4743-4749. 10.1074/jbc.M310281200.
29. Singh A., Karnoub A.E., Palmby T.R., Lengyel E., Sondek J., Der C.J. Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation. Oncogene 2004, 23:9369-9380. 10.1038/sj.onc.1208182.
30. Matos P., Jordan P. Expression of Rac1b stimulates NF-kappaB-mediated cell survival and G1/S progression. Exp. Cell Res 2005, 305:292-299. 10.1016/j.yexcr.2004.12.029.
31. Matos P., Jordan P. Increased Rac1b expression sustains colorectal tumor cell survival. Mol. Cancer Res 2008, 6:1178-1184. 10.1158/1541-7786.MCR-08-0008.
32. Alonso-Espinaco V., Cuatrecasas M., Alonso V., Escudero P., Marmol M., Horndler C., et al. RAC1b overexpression correlates with poor prognosis in KRAS/BRAF WT metastatic colorectal cancer patients treated with first-line FOLFOX/XELOX chemotherapy. Eur. J. Cancer 2014, 50:1973-1981. 10.1016/j.ejca.2014.04.019.
33. Moyer M.P., Manzano L.A., Merriman R.L., Stauffer J.S., Tanzer L.R. NCM460, a normal human colon mucosal epithelial cell line. In Vitro Cell. Dev. Biol. Anim 1996, 32:315-317.
34. Ahmed D., Eide P.W., Eilertsen I.A., Danielsen S.A., Eknæs M., Hektoen M., et al. Epigenetic and genetic features of 24 colon cancer cell lines. Oncogenesis 2013, 2:e71. 10.1038/oncsis.2013.35.
35. Itahana K., Campisi J., Dimri G.P. Methods to detect biomarkers of cellular senescence: the senescence-associated beta-galactosidase assay. Methods Mol. Biol 2007, 371:21-31.
36. Krimpenfort P., Ijpenberg A., Song J.-Y., van der Valk M., Nawijn M., Zevenhoven J., et al. p15Ink4b is a critical tumour suppressor in the absence of p16Ink4a. Nature 2007, 448:943-946. 10.1038/nature06084.
37. Benavides M.A., Hagen K.L., Fang W., Du P., Lin S., Moyer M.P., et al. Suppression by L-methionine of cell cycle progression in LNCaP and MCF-7 cells but not benign cells. Anticancer Res 2010, 30:1881-1885.
38. Lee K., Chen Q.K., Lui C., Cichon M.A., Radisky D.C., Nelson C.M. Matrix compliance regulates Rac1b localization, NADPH oxidase assembly, and epithelial-mesenchymal transition. Mol. Biol. Cell 2012, 23:4097-4108. 10.1091/mbc.E12-02-0166.
39. Matos P., Jordan P. Rac1, but not Rac1B, stimulates RelB-mediated gene transcription in colorectal cancer cells. J. Biol. Chem 2006, 281:13724-13732. 10.1074/jbc.M513243200.
40. Romagosa C., Simonetti S., López-Vicente L., Mazo A., Lleonart M.E., Castellvi J., et al. p16(Ink4a) overexpression in cancer: a tumor suppressor gene associated with senescence and high-grade tumors. Oncogene 2011, 30:2087-2097. 10.1038/onc.2010.614.
41. Minoo P., Moyer M.P., Jass J.R. Role of BRAF-V600E in the serrated pathway of colorectal tumourigenesis. J. Pathol 2007, 212:124-133. 10.1002/path.2160.
42. Jabbur J.R., Huang P., Zhang W. DNA damage-induced phosphorylation of p53 at serine 20 correlates with p21 and Mdm-2 induction in vivo. Oncogene 2000, 19:6203-6208. 10.1038/sj.onc.1204017.
43. Ungefroren H., Sebens S., Giehl K., Helm O., Groth S., Fändrich F., et al. Rac1b negatively regulates TGF-β1-induced cell motility in pancreatic ductal epithelial cells by suppressing Smad signalling. Oncotarget 2014, 5:277-290.
44. Radisky D.C., Levy D.D., Littlepage L.E., Liu H., Nelson C.M., Fata J.E., et al. Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability. Nature 2005, 436:123-127. 10.1038/nature03688.
45. Matos P., Kotelevets L., Goncalves V., Henriques A., Zerbib P., Moyer M.P., et al. Ibuprofen inhibits colitis-induced overexpression of tumor-related Rac1b. Neoplasia 2013, 15:102-111.
46. O'Connor P.M., Lapointe T.K., Beck P.L., Buret A.G. Mechanisms by which inflammation may increase intestinal cancer risk in inflammatory bowel disease. Inflamm. Bowel Dis 2010, 16:1411-1420. 10.1002/ibd.21217.
47. Ullman T.A., Itzkowitz S.H. Intestinal inflammation and cancer. Gastroenterology 2011, 140:1807-1816. 10.1053/j.gastro.2011.01.057.